Tower Research Capital LLC (Trc) Athira Pharma, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,115 shares of ATHA stock, worth $3,017. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,115Holding current value
$3,017% of portfolio
0.0%Shares
14 transactions
Others Institutions Holding ATHA
# of Institutions
66Shares Held
16.9MCall Options Held
112KPut Options Held
68K-
Perceptive Advisors LLC New York, NY5.4MShares$3.19 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.61MShares$951,7070.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$880,7470.04% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$880,7470.39% of portfolio
-
Black Rock Inc. New York, NY676KShares$398,9830.0% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $22.3M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...